| 13.39 0.38 (2.92%) | 03-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.84 |
1-year : | 19.67 |
| Resists | First : | 14.42 |
Second : | 16.84 |
| Pivot price | 13.26 |
|||
| Supports | First : | 12.92 |
Second : | 12 |
| MAs | MA(5) : | 13.12  |
MA(20) : | 13.21 |
| MA(100) : | 13.75 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 57.3 |
D(3) : | 51.8 |
| RSI | RSI(14): 49.8 |
|||
| 52-week | High : | 17.23 | Low : | 10.92 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SI ] has closed below upper band by 33.1%. Bollinger Bands are 67.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 13.41 - 13.49 | 13.49 - 13.57 |
| Low: | 12.5 - 12.58 | 12.58 - 12.67 |
| Close: | 12.85 - 13 | 13 - 13.16 |
Shoulder Innovations, Inc. manufactures medical devices. It has developed a shoulder replacement system. The company was founded by Stephen B. Gunther and Michael DeVries in 2009 and is headquartered in Grand Rapids, MI.
Tue, 03 Mar 2026
SI: AI-driven planning, innovative implants, and robotics fuel rapid growth in shoulder arthroplasty - TradingView
Mon, 02 Mar 2026
Shoulder Innovations Adds Medtech Veteran Drew Hykes to Board - TipRanks
Mon, 02 Mar 2026
Medtech leader Drew Hykes joins Shoulder Innovations (NYSE: SI) board after Pardo exit - Stock Titan
Mon, 02 Mar 2026
Shoulder Innovations Appoints MedTech Veteran Drew Hykes to Board of Directors - Sahm
Tue, 17 Feb 2026
Shoulder Innovations, Inc. (NYSE:SI) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Thu, 12 Feb 2026
Shoulder Innovations to Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026 - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Specialties
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|